Application of SPECT/PET to 70 patients with lymphoma:monitoring response to therapy

目的 探讨SPECT/PET18F-FDG检查对淋巴瘤患者化疗早期及治疗后评价疗效的应用价值.方法 回顾性分析我院1998年至2008年病理活检和免疫组化确诊的70例淋巴瘤患者的83例次SPECT/PET检查结果,预后的单因素分析采用生存分析法.结果 40例患者化疗2～4个疗程后进行SPECT/PET检查,结果阳性者和阴性者中位无进展生存(PFS)期分别为5.5个月和15.5个月,2年的PFS率分别为12.5%和66.8%,两组之间差异有统计学意义(P＜0.01);中位总体生存(OS)期分别为12.5个月和17.0个月,1年OS率分别为28.8%和94.1%,两组之间差异有统计学意义(P=0.003).43例患者在完成全部疗程后行SPECT/PET检查,结果阳性者和阴性者中位PFS期分别为10个月和23个月,2年的PFS率分别为23.3%和83.2%,两组之间差异有统计学意义(P＜0.001);中位OS期分别为17个月和27个月,2年OS率分别为60.0%和100%,两组之间差异有统计学意义(P=0.001).结论 SPECT/PET检查结果对淋巴瘤患者监测疗效和判断预后有重要意义.OBJECTIVE: To evaluate the image of SPECT/PET (18)F-FDG in monitoring response to therapy for lymphoma patients. METHODS: A retrospective study was performed in 83 SPECT/PET studies for 70 patients with lymphoma from 1998 to 2008 in our hospital. The risk factors for survival rate were analyzed by univariate analysis. RESULTS: Forty patients received SPECT/PET after 2 - 4 cycles of chemotheraphy, the median PFS in patients with positive and negative group were 5.5 months and 15.5 months, 2-year PFS were 12.5% and 66.8%; the median OS were 12.5 months and 17 months, and 1-year OS were 28.8% and 94.1%, respectively, all being of significant difference between two groups (P = 0.003). Forty-three patients performed posttreatment SPECT/PET, the median PFS in patients with positive and negative group were 10 months and 23 months, the 2-year PFS were 23.3% and 83.2%; the median OS were 17 months and 27 months and the 2-year OS were 60.0% and 100% respectively, all being of significant difference (P = 0.001). CONCLUSION: SPECT/PET has significant value in monitoring response to therapy and predicting prognosis for patients with lymphoma.PubMed中文核心期刊要目总览(PKU)中国科技核心期刊(ISTIC)中国科学引文数据库(CSCD)010667-6703